

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM389942

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Hercules Capital, Inc., formerly known as Hercules Technology Growth Capital, Inc.		06/29/2016	Corporation: MARYLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Aegerion Pharmaceuticals, Inc.		
<b>Street Address:</b>	One Main Street, Suite 800		
<b>City:</b>	Cambridge		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02142		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3300046	AEGERION	
<b>Registration Number:</b>	3448427	AEGERION PHARMACEUTICALS, INC.	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6175231231		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6175701000		
<b>Email:</b>	rthomas@goodwinprocter.com		
<b>Correspondent Name:</b>	Ryan E. Thomas		
<b>Address Line 1:</b>	Goodwin Procter LLP		
<b>Address Line 2:</b>	100 Northern Avenue		
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02210		
<b>ATTORNEY DOCKET NUMBER:</b>	121052/163970		
<b>NAME OF SUBMITTER:</b>	Ryan E. Thomas		
<b>SIGNATURE:</b>	/RET/		
<b>DATE SIGNED:</b>	07/01/2016		
<b>Total Attachments: 17</b>			

OP \$65.00 3300046

source=Hercules-Aegerion IP Release#page1.tif  
source=Hercules-Aegerion IP Release#page2.tif  
source=Hercules-Aegerion IP Release#page3.tif  
source=Hercules-Aegerion IP Release#page4.tif  
source=Hercules-Aegerion IP Release#page5.tif  
source=Hercules-Aegerion IP Release#page6.tif  
source=Hercules-Aegerion IP Release#page7.tif  
source=Hercules-Aegerion IP Release#page8.tif  
source=Hercules-Aegerion IP Release#page9.tif  
source=Hercules-Aegerion IP Release#page10.tif  
source=Hercules-Aegerion IP Release#page11.tif  
source=Hercules-Aegerion IP Release#page12.tif  
source=Hercules-Aegerion IP Release#page13.tif  
source=Hercules-Aegerion IP Release#page14.tif  
source=Hercules-Aegerion IP Release#page15.tif  
source=Hercules-Aegerion IP Release#page16.tif  
source=Hercules-Aegerion IP Release#page17.tif

## TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (the "Release") is made this 29<sup>th</sup> day of June, 2016 (the "Release Date") by **HERCULES CAPITAL, INC., FORMERLY KNOWN AS HERCULES TECHNOLOGY GROWTH CAPITAL, INC.** ("**Lender**"), a Maryland corporation, for the benefit of **AEGERION PHARMACEUTICALS, INC.**, a Delaware corporation (the "Grantor").

WHEREAS, Grantor has entered into that certain Loan and Security Agreement, dated as of March 20, 2007, (as at any time prior to the date hereof amended, supplemented or otherwise modified, the "Loan Agreement").

WHEREAS, in connection with a Second Amendment to Loan and Security Agreement, dated as of July 2, 2009, Grantor granted to Lender a security interest in Grantor's intellectual property.

WHEREAS, in accordance with the Loan Agreement, Grantor has entered into that certain Intellectual Property Security Agreement, dated as of July 2, 2009 with Lender (as at any time prior to the date hereof amended, supplemented or otherwise modified, the "IP Security Agreement"), pursuant to which Grantor, to secure performance of Grantor's obligations under the Loan Agreement, granted to Lender a security interest in all of Grantor's right, title and interest in Grantor's intellectual property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and, including without limitation, all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits) (collectively the "Intellectual Property Collateral").

WHEREAS, Lender has filed with the United States Patent and Trademark Office (the "USPTO") a notice of security interest in the Intellectual Property Collateral.

WHEREAS, Grantor has paid all outstanding amounts currently owing under the Loan Agreement and the other financing documents (other than the Warrant and any inchoate indemnification obligations) executed in connection therewith and has requested that Lender release its security interest in the Intellectual Property Collateral, and Lender desires to release its security interest in the Intellectual Property Collateral.

NOW THEREFORE, in consideration thereof and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lender agrees as follows:

1. Release of Security Interest. Effective as of the Release Date, Lender hereby irrevocably and forever terminates, releases and discharges any and all security interests and any other rights, title and interest it has in, to and under the Intellectual Property Collateral granted to Lender by Grantor under the Loan Agreement and IP Security Agreement.

2. Recordation of Release. Lender understands and agrees that this Release may be recorded by or for Grantor with the USPTO.


3. Further Actions. Lender further agrees to execute any other documents and take any further action reasonably necessary in any state, country or jurisdiction that Grantor may reasonably require to effect the intent and purpose of this Release, provided that all such documents are to be prepared by counsel to Grantor and the cost and expense of such documents and actions shall be borne solely by Grantor.

4. Capitalized Terms. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Loan Agreement and/or IP Security Agreement, as applicable.

[Signature page follows]

IN WITNESS WHEREOF, Lender has caused this Release to be executed as an instrument under seal by its duly authorized officer as of the Release Date.

**HERCULES CAPITAL, INC.,**

By:   
Name: \_\_\_\_\_  
Title: 

**EXHIBIT A**  
**COPYRIGHTS**

**None**

## EXHIBIT B

## PATENTS/PATENT APPLICATIONS

Application #:	Filing Date:	Country	Application Title:	Patent #:	Issue Date:
60/788,616	03-Apr-2006	US	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
60/727664	18-Oct-2005	US	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2006304689	18-Oct-2006	AU	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2626461	18-Oct-2006	CA	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
06836404.1	18-Oct-2006	EP	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2008-536810	18-Oct-2006	JP	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
12/090539	27-Jun-2008	US	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2006304531	18-Oct-2006	AU	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2626422	18-Oct-2006	CA	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
06817090.1	18-Oct-2006	EP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2008-536750	18-Oct-2006	JP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
12/197621	25-Aug-2008	US	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
US06/40637	18-Oct-2006	WO	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2006304541	18-Oct-2006	AU	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2626441	18-Oct-2006	CA	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		

Aegerion Pharmaceuticals Patents-Owned and Licensed

06817093.5	18-Oct-2006	EP	DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
2008-536751	18-Oct-2006	JP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
11/582833	18-Oct-2006	US	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
US06/40640	18-Oct-2006	WO	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
06817092.7	18-Oct-2006	EP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
11/582876	18-Oct-2006	US	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
US06/40639	18-Oct-2006	WO	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	
60/876280	21-Dec-2006	US	METHODS FOR TREATING OBESITY	
11/962383	21-Dec-2007	US	METHODS FOR TREATING OBESITY	
US07/26300	21-Dec-2007	PCT	METHODS FOR TREATING OBESITY	
2007338625	21-Dec-2007	AU	METHODS FOR TREATING OBESITY	
	21-Dec-2007	CA	METHODS FOR TREATING OBESITY	
	21-Dec-2007	EP	METHODS FOR TREATING OBESITY	
	21-Dec-2007	JP	METHODS FOR TREATING OBESITY	
60/909833	03-Apr-2007	US	METHODS FOR TREATING HEPATITIS C	
US08/58992	01-Apr-2008	PCT	METHODS FOR TREATING HEPATITIS	
61/144542	14-Jan-2009	US	DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN AN MAMMAL	
61/144544	14-Jan-2009	US	METHODS FOR TREATING OBESITY AND DISORDERS ASSOCIATED WITH HYPERLIPEMIA IN A MAMMAL	



Aegerion Pharmaceuticals Patents-Owned and Licensed

Patent Applications licensed from UPenn

US06/40953	18-Oct-2006	WO	METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL	
2005221656	07-Mar-2005	AU	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
2,558,766	07-Mar-2005	CA	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
05724887.4	07-Mar-2005	EP	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
	07-Mar-2005	IN	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
2007-502093	07-Mar-2005	JP	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
10-2006-7020836	07-Mar-2005	KR	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
549721	07-Mar-2005	NZ	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
10/591923	05-Sep-2006	US	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
60/550915	05-Mar-2004	US	METHODS FOR TREATING DISORDERS	

Aegerion Pharmaceuticals Patents-Owned and Licensed

US05/007435	07-Mar-2005	W/O	OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS		
			METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS		

Patents/Applications Licensed from Bayer

333677	28-Sep-1995	AR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	256140M	31-Oct-2005
95114877.4	21-Sep-1995	AT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
32920/95	27-Sep-1995	AU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	700609	22-Apr-1999
95114877.4	21-Sep-1995	BE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
950624	04-Oct-1995	BY	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	5422	24-Apr-2003
2159546	29-Sep-1995	CA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
95114877.4	21-Sep-1995	CH	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
1513-95	02-Oct-1995	CL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	40,031	19-Jul-1999
95117117.8	04-Oct-1995	CN	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	52189	10-Dec-1999
98126085.3	04-Oct-1995	CN	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	188667	05-Jan-2005
2567-95	03-Oct-1995	CZ	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	291348	11-Dec-2002
95114877.4	21-Sep-1995	DE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	59510839.3	10-Apr-1996
95114877.4	21-Sep-1995	DK	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
5232	26-Sep-1995	DO	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	5232	11-Apr-1996
0116-95	02-Oct-1995	DZ	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
P9500071	03-Oct-1995	EE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	03527	15-Oct-2001

Aegerion Pharmaceuticals Patents-Owned and Licensed

95114877.4	21-Sep-1995	EP	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	ES	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
954681	03-Oct-1995	FI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	113048	27-Feb-2004
20002693	08-Dec-2000	FI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	108791	28-Mar-2002
95114877.4	21-Sep-1995	FR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	GB	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	GR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
98104346.6	19-May-1998	HK	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	HK1005139	21-May-2004
9160/95	29-Sep-1995	HN	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	3769181	14-Apr-2000
P950505A	27-Sep-1995	HR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	P950505	03-Apr-2002
9502891	03-Oct-1995	HU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
P952018	04-Oct-1995	ID	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	ID0009015	21-Oct-2002
95114877.4	21-Sep-1995	IE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
115493	02-Oct-1995	IL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	115493	30-Jan-2000
129641	02-Oct-1995	IL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	129641	30-Jan-2000
95114877.4	21-Sep-1995	IT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
279664/95	03-Oct-1995	JP	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
10-1995-33651	02-Oct-1995	KR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	10-355986	26-Sep-2002
95114877.4	21-Sep-1995	LT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	LU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	LV	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
24026	02-Oct-1995	MA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	23682	01-Jul-1996

Aegerion Pharmaceuticals Patents-Owned and Licensed

95114877.4	21-Sep-1995	MC	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
954196	03-Oct-1995	MX	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	193845	
9502964	04-Oct-1995	MY	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	117282-A	30-Jun-2004
95114877.4	21-Sep-1995	NL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
953930	03-Oct-1995	NO	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	305365	18-May-1999
280130	29-Sep-1995	NZ	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	280130	
51415	03-Oct-1995	PH	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	31400	29-Oct-1998
310756	03-Oct-1995	PL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	183154	09-Oct-2001
95114877.4	21-Sep-1995	PT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95117070	03-Oct-1995	RU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	2157803	20-Oct-2000
95114877.4	21-Sep-1995	SE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
9501478-3	03-Oct-1995	SG	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	63528	30-Mar-1999
95114877.4	21-Sep-1995	SI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
1239-95	03-Oct-1995	SK	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	284260	05-Oct-2004
62-95	04-Oct-1995	SV	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	154-1-309	11-Sep-2000
28216	02-Oct-1995	TH	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	13768	01-Nov-2002
1323	02-Oct-1995	TI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
95098	02-Oct-1995	TN	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	17943	
84-110247	02-Oct-1995	TW	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	140388	04-Jan-2002
95104372	03-Oct-1995	UA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	44700	15-Mar-2002
08/535698	28-Sep-1995	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	5,684,014	04-Nov-1997
08/887781	03-Jul-1997	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,245,775	12-Jun-2001
09/313035	17-May-1999	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,265,431	24-Jul-2001

Aegerion Pharmaceuticals Patents-Owned and Licensed

09/734955	11-Dec-2000	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES			
09/814263	21-Mar-2001	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,479,503		12-Nov-2002
10/198315	18-Jul-2002	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,858,622		22-Feb-2005
95-8297	03-Oct-1995	ZA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	95-8297		
2413277	08-Jun-2001	CA	USE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS FOR REDUCING THE NUMBER OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES (PPTRL)			
503264-2002	08-Jun-2001	JP	USE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS FOR REDUCING THE NUMBER OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES (PPTRL)			
11/388810	24-Mar-2006	US	USE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS FOR REDUCING THE NUMBER OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES (PPTRL)			
2201435	01-Apr-1997	CA	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOL-CARBOXYLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	2201435		12-Dec-2006
97104941.6	24-Mar-1997	DE	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOL-CARBOXYLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	59710487.5		30-Jul-2003
97104941.6	24-Mar-1997	EP	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOL-CARBOXYLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829		30-Jul-2003
97104941.6	24-Mar-1997	ES	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOL-CARBOXYLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829		30-Jul-2003

Aegerion Pharmaceuticals Patents-Owned and Licensed

97104941.6	24-Mar-1997	FR	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
97104941.6	24-Mar-1997	GB	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
97104941.6	24-Mar-1997	IT	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
96351-97	01-Apr-1997	JP	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	4235268	
97104941.6	24-Mar-1997	SE	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	97104941.6	30-Jul-2003
08/829566	31-Mar-1997	US	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	5,952,498	14-Sep-1999
09/307980	10-May-1999	US	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1,2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	6,774,236	10-Aug-2004
P000103129	22-Jun-2000	AR	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS		

Aegerion Pharmaceuticals Patents-Owned and Licensed

1242	08-Jun-2000	BS	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS	1242	29-Jan-2002
2000-100	15-Jun-2000	HN	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS	4029-431 -VII	18-Oct-2001
505893-2001	13-Jun-2000	JP	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS		
07733696.4	18-May-2006	EP	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
PCT/GB2007/050275	18-May-2007	WO	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
11/750566	18-May-2007	US	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
200725994	18-May-2007	AU	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
2652751	18-May-2007	CA	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
510557/09	18-May-2008	JP	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		

Patents/Applications licensed from BMS

08/854,311	12-May-1997	US	METHOD FOR LOWERING SERUM LIPID LEVELS EMPLOYING AN MTP INHIBITOR IN COMBINATION WITH ANOTHER CHOLESTEROL LOWERING DRUG	5,883,109	16-Mar-1999
08/486,929	07-Jun-1995	US	MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN	6,492,365	10-Dec-2002
199647631	01-Feb-1996	AU	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	699865	17-Dec-1998
2,213,466	01-Feb-1996	CA	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD		
96903604.5	01-Feb-1996	DE	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER	0886637	04-May-2005

Aegerion Pharmaceuticals Patents-Owned and Licensed

96903604.5	01-Feb-1996	EP	PROTEIN AND METHOD INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	ES	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	FR	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	GB	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
116,917	26-Jan-1996	IL	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	116,917	03-Dec-2000
96903604.5	01-Feb-1996	IT	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
525679/96	01-Feb-1996	JP	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	4036244	
08/472,067	06-Jun-1995	US	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	5,739,135	14-Apr-1998
08/548,811	11-Jan-1996	US	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	5,712,279	27-Jan-1998
08/898,303	21-Jul-1997	US	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	6,066,650	23-May-2000

Patent Applications licensed from UTexas

US08/51097	15-Jan-2008	PCT	TREATING HEPATITIS C	
11/657856	24-Jan-2007	US	TREATING HEPATITIS C	

Patent/Patent Applications licensed from Duke  
US6207855



Aegerion Pharmaceuticals Patents-Owned and Licensed

US6359167  
US6488951  
US6583311  
US7015347  
US6459182  
US7049308  
US7259250  
US6538166  
US6887944  
US7030238  
US6472390  
USSN 11/812399  
PCT/US2007/016598

**TRADEMARK**  
**REEL: 005825 FRAME: 0330**

**EXHIBIT C**

**TRADEMARKS/TRADEMARK APPLICATIONS**

<b>Trademark</b>	<b>Status</b>	<b>Application No. Registration No.</b>	<b>Application Date Registration Date</b>
<b>AEGERION</b>	Pending	1327744	11-Dec-2006
<i>Country:</i> Canada		-	
<b>AEGERION</b>	Pending		12-Dec-2006
<i>Country:</i> China (Peoples Republic)			
<b>AEGERION</b>	Registered	5547054	12-Dec-2006
		5547054	12-Dec-2006
<i>Country:</i> European Community			
<b>AEGERION</b>	Registered	2006-114211	11-Dec-2006
		5044877	27-Apr-2007
<i>Country:</i> Japan			
<b>AEGERION</b>	Registered	78906083	12-Jun-2006
		3300046	25-Sep-2007
<i>Country:</i> United States of America			
<b>AEGERION (logo)</b>	Registered	5547062	12-Dec-2006
		5547062	12-Dec-2006
<i>Country:</i> European Community			
<b>AEGERION (logo)</b>	Registered	2006-114212	11-Dec-2006
		5044878	27-Apr-2007
<i>Country:</i> Japan			
<b>AEGERION and (logo)</b>	Pending		12-Dec-2006
<i>Country:</i> China (Peoples Republic)			
<b>AEGERION PHARMACEUTICALS, INC. (color logo)</b>	Registered	77283527	19-Sep-2007
		3448427	17-Jun-2008
<i>Country:</i> United States of America			
<b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Pending	1,388,054	19-Mar-2008
<i>Country:</i> Canada			
<b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Pending	6,605,387	19-Mar-2008
<i>Country:</i> China (Peoples Republic)			

<b>Trademark</b>	<b>Status</b>	<b>Application No. Registration No.</b>	<b>Application Date Registration Date</b>
<b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Pending	6765606	19-Mar-2008
<i>Country:</i> European Community <b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Registered	301075392 301075392	19-Mar-2008 9-Nov-2008
<i>Country:</i> Hong Kong <b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Pending	1667251	19-Mar-2008
<i>Country:</i> India <b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Pending	2008-020650	19-Mar-2008
<i>Country:</i> Japan <b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Registered	921879 1058239	19-Mar-2008 29-Aug-2008
<i>Country:</i> Mexico <b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Pending	2008/06216	19-Mar-2008
<i>Country:</i> South Africa <b>AEGERION PHARMACEUTICALS, INC. (logo)</b>	Registered	97012128 1340728	19-Mar-2008
<i>Country:</i> Taiwan			